Global Parkinson’s Disease Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2022–2031
Overview: Parkinson’s disease is one of the most prevalent neurodegenerative disorders, which progresses with age because of damaged dopaminergic cells in the brain. Bradykinesia, rigidity, postural instability, and tremors are the symptoms of the Parkinson’s disease. Huge patient pool and rising rate of diagnosis are the significant factors driving the market growth. The Parkinson’s Disease Foundation has stated that nearly 10 million people are suffering from this disorder globally. The highest frequency of this disorder is observed in developed countries, and in the US, almost 60,000 new cases are reported annually.
Access Free PDF With Graphs and Charts : https://www.sdki.jp/sample-request-107439
PD is an idiopathic disease for which the cause of the occurrence is still unknown, hence only symptomatic drugs are available in the market for the treatment. Furthermore, the disorder is diagnosed in the final stages when the majority of the cells that produce dopamine lose their functionality. This is demanding more innovative and novel drugs for the treatment.
Request Sample For More Insights : https://www.sdki.jp/sample-request-107439
Market Analysis: The “Global Parkinson’s Disease Drugs Market” is estimated to witness a CAGR of 7.2% during the forecast period 2018–2024. The market is analyzed based on two segments – drug class and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America accounts for the largest share of the market, followed by Europe, Asia Pacific, and Rest of the World. More than 40% of the market is occupied by Europe, with Germany being the major contributor to the market growth.
Drug Class Analysis: Based on drug classes, the market is segmented into levodopa, MAO-B inhibitors, COMT inhibitors, dopamine agonists, anticholinergics, and others. Levodopa is the most attractive drug in the market owing to its highly effective treatment in controlling the motor symptoms throughout the stages of Parkinson’s disease. Recently, in January 2018, Adamas Pharmaceuticals Inc. launched Gocovri for the treatment of dyskinesia in individuals with PD, who are taking levodopa. This is the original drug indicated explicitly for dyskinesia, which is technologically advanced with the long-term use of levodopa.
Key Players: The major players in the market include Novartis, Roche, AbbVie, Teva Pharmaceutical, Pfizer, STADA Arzneimittel AG, GSK, Valeant, Merck & Co. Inc., and Amneal Pharmaceuticals Inc.
Global Parkinson\’s Disease Drugs Market
Global Drug Eluting Stents Market
Global Healthcare X-Ray Detectors Market
Global Cardiac Assist Devices Market
North America In Vitro Diagnostics Market
Global Non-invasive Prenatal Testing (NIPT) Market
Global Ventricular Assist Devices Market
Pulse Oximetry Market
Global qPCR and dPCR Market
Global Arthroscopy Devices Market